Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Sep 14, 2026
Reporting period
Not applicable
Filed with the SEC
Sep 17, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001967722-26-000002
Filed / recorded
Sep 17, 2026, 12:02 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Krystal Biotech, Inc.
Issuer CIK
1711279
Ticker
KRYS
Reporting person
Catherine Mazzacco
Relationship
Director
Security
Stock Option (Right to Buy)
Table
Derivative (Table II)
Transaction date
Sep 14, 2026
Transaction code
A
Shares / units
1,187
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
1,187
Ownership form
Direct
Amendment
No
Footnotes from the filing
The stock options vest in full on September 14, 2027, subject to continued service on the Company's Board of Directors through such date and to earlier vesting in certain circumstances described in the Company's Non-Employee Director Compensation Policy as in effect on the date of grant.